These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 18041673)
21. AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. Drug highlights. 14-18th November 2005, Philadelphia, PA, USA. Garvey R IDrugs; 2006 Jan; 9(1):9-12. PubMed ID: 16374723 [No Abstract] [Full Text] [Related]
22. AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. Emerging targets and new agents from academia. 14-18th November 2005, Philadelphia, PA, USA. Garvey R IDrugs; 2006 Jan; 9(1):6-8. PubMed ID: 16374722 [No Abstract] [Full Text] [Related]
23. Targeting polo-like kinase: learning too little too late? Olmos D; Swanton C; de Bono J J Clin Oncol; 2008 Dec; 26(34):5497-9. PubMed ID: 18955441 [No Abstract] [Full Text] [Related]
24. AACR-NCI-EORTC-15th symposium molecular targets and cancer therapeutics: emerging targets and pharmacodynamics. Mayfield R IDrugs; 2004 Jan; 7(1):22-5. PubMed ID: 14968810 [No Abstract] [Full Text] [Related]
25. PLK1 as an oncology target: current status and future potential. McInnes C; Wyatt MD Drug Discov Today; 2011 Jul; 16(13-14):619-25. PubMed ID: 21601650 [TBL] [Abstract][Full Text] [Related]
26. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Montagnoli A; Moll J; Colotta F Clin Cancer Res; 2010 Sep; 16(18):4503-8. PubMed ID: 20647475 [TBL] [Abstract][Full Text] [Related]
32. Molecular targets and cancer therapeutics. 19th annual AACR-NCI-EORTC conference October 22-26, 2007, San Francisco, California, USA. Lukan CD Eur J Cancer; 2008 Jan; 44(2):168. PubMed ID: 18335585 [No Abstract] [Full Text] [Related]
33. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Warner SL; Gray PJ; Von Hoff DD Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798 [TBL] [Abstract][Full Text] [Related]
34. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080 [TBL] [Abstract][Full Text] [Related]
35. AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA. Veryard C IDrugs; 2006 Jan; 9(1):1-3. PubMed ID: 16374720 [No Abstract] [Full Text] [Related]
36. EORTC-NCI-AACR--14th Symposium. Molecular targets and cancer therapeutics--part I. 19-22 November 2002, Frankfurt, Germany. Patterson C IDrugs; 2003 Jan; 6(1):23-6. PubMed ID: 12838967 [No Abstract] [Full Text] [Related]
38. 1999 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Development, and Clinical Validation. Washington, DC, USA. November 16-19, 1999. Abstracts. Clin Cancer Res; 1999 Nov; 5(11 Suppl):3729s-3897s. PubMed ID: 10590781 [No Abstract] [Full Text] [Related]
39. Cdc7 as a potential new target for cancer therapy. Ito S; Taniyami C; Arai N; Masai H Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266 [TBL] [Abstract][Full Text] [Related]
40. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Medema RH; Lin CC; Yang JC Clin Cancer Res; 2011 Oct; 17(20):6459-66. PubMed ID: 22003073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]